E
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Price:
1 646.8
INR
1.01%
Market Cap:
₹312.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
E
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
IN |
|
Dallah Healthcare Company SJSC
SAU:4004
|
SA |
|
Jindal Steel And Power Ltd
NSE:JINDALSTEL
|
IN |
|
P
|
Pluk Phak Praw Rak Mae PCL
SET:OKJ
|
TH |
|
Plaid Inc
TSE:4165
|
JP |
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
NL |
|
S
|
Suning Universal Co Ltd
SZSE:000718
|
CN |
|
C
|
Cybozu Inc
TSE:4776
|
JP |
|
Century Co Ltd
KRX:002420
|
KR |
|
Sun* Inc
TSE:4053
|
JP |
|
F
|
Feishang Anthracite Resources Ltd
HKEX:1738
|
CN |
|
Promisia Healthcare Ltd
NZX:PHL
|
NZ |
|
U
|
UDS Group Inc
OTC:UDSG
|
US |
Multiples-Based Value
The Multiples-Based Value of one EMCURE stock under the Base Case scenario is hidden INR. Compared to the current market price of 1 646.8 INR, Emcure Pharmaceuticals Ltd is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EMCURE Multiples-Based Value
LOCKED
Multiples Across Competitors
EMCURE Competitors Multiples
Emcure Pharmaceuticals Ltd Competitors
Emcure Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
E
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
312.2B INR | 3.5 | 35.9 | 18.5 | 24.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
855.1B USD | 13.1 | 41.4 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.7B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
229B GBP | 5.2 | 29.7 | 16.4 | 23.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
291.8B USD | 4.5 | 16 | 9.9 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.8B CHF | 5.1 | 20.5 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.6B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| UK |
|
GSK plc
XETRA:GS71
|
99.8B EUR | 2.7 | 15.2 | 8.2 | 10.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
